Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03007732 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
A Phase 2 study of Prostatic Neoplasms, sponsored by David Oh.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT03007732 is a Phase 2 study of Prostatic Neoplasms that has completed, run by David Oh. The registered enrollment target is 23 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03007732, a Phase 2 study of Prostatic Neoplasms, has completed, sponsored by David Oh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive oligometastatic prostate cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Prednisone
- DRUG Leuprolide acetate
- DRUG Abiraterone Acetate
- DRUG SD-101
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-05-17 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03007732
The ClinicalTrials.gov registry entry for NCT03007732 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower). The listed sponsor is David Oh, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03007732 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03007732 about?
NCT03007732 is a clinical study titled "Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT". This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive oligometastatic prostate cancer.
What is the current status of trial NCT03007732?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-05-17. Estimated completion is 2025-03-31.
What conditions does trial NCT03007732 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT03007732?
The interventions under investigation include: Pembrolizumab (DRUG), Prednisone (DRUG), Leuprolide acetate (DRUG), Abiraterone Acetate (DRUG), SD-101 (DRUG).
Who is sponsoring clinical trial NCT03007732?
This trial is sponsored by David Oh, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03007732 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
RECRUITING · Phase 2
-
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
RECRUITING · Phase 2
-
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.